Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.

about

Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report.

Item

http://www.wikidata.org/entity/Q52604951

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Durable remission in a patient ...... d lenalidomide: A case report.

@en

Durable remission in a patient ...... d lenalidomide: A case report.

@nl

type

Item

label

Durable remission in a patient ...... d lenalidomide: A case report.

@en

Durable remission in a patient ...... d lenalidomide: A case report.

@nl

prefLabel

Durable remission in a patient ...... d lenalidomide: A case report.

@en

Durable remission in a patient ...... d lenalidomide: A case report.

@nl

P1476

Durable remission in a patient ...... d lenalidomide: A case report.

@en

P2093

Binbin Lai

http://www.w3.org/2001/XMLSchema#string

Guifang Ouyang

http://www.w3.org/2001/XMLSchema#string

Huiling Zhu

http://www.w3.org/2001/XMLSchema#string

Kaihong Xu

http://www.w3.org/2001/XMLSchema#string

Lixia Sheng

http://www.w3.org/2001/XMLSchema#string

Qitian Mu

http://www.w3.org/2001/XMLSchema#string

Yi Wang

http://www.w3.org/2001/XMLSchema#string

Yi Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.

Expanding role of lenalidomide in hematologic malignancies

Immunomodulatory drugs.

Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification.

Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Mixed-phenotype acute leukemia: historical overview and a new definition.

Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

P304

e0294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1097/MD.0000000000010294

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29620650

http://www.w3.org/2001/XMLSchema#string

P932

5902271

http://www.w3.org/2001/XMLSchema#string